---
layout: default
title: Activated Charcoal Ambrosia Artemisiifolia Whole E
parent: Model Prediction Only (L5)
nav_order: 171
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Ambrosia Artemisiifolia Whole E
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Multi-Component Combination (Homogeneous Plant/Mineral Combination): Unable to Assess Drug Repurposing Indication

## One-Sentence Summary

This candidate drug is a multi-component combination formulation containing nine active ingredients, including activated charcoal, ragweed, eyebright, onion, phosphorus, pulsatilla, solidago, nux vomica, and sulfur, representing a typical homeopathic combination formula.
The TxGNN model **produced no new indication predictions for this drug**, and query logs indicate no DrugBank record (no DrugBank ID) exists.
Available data are insufficient to support the drug repurposing assessment workflow; this report documents current status and provides remediation recommendations.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No record (original indication data missing) |
| Predicted New Indication | None (TxGNN produced no prediction results) |
| TxGNN Prediction Score | Cannot be calculated |
| Evidence Level | L5 (model prediction not applicable, no research support) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, TxGNN **produced no drug repurposing predictions for this multi-component combination**, therefore this section cannot perform standard mechanistic association analysis.

Based on component composition, this formulation is classified as a **homeopathic combination formula**, with ingredients including:
- **Ambrosia artemisiifolia** (ragweed): traditionally used for allergic rhinitis
- **Euphrasia stricta** (eyebright): traditionally used for ocular allergy symptoms
- **Solidago virgaurea** (solidago): traditionally used for respiratory/sinusitis conditions
- **Pulsatilla vulgaris** (pulsatilla): traditionally used for respiratory symptoms
- **Allium cepa (onion)** / **Sulfur** / **Phosphorus**: commonly used foundational ingredients in homeopathic therapy
- **Strychnos nux-vomica seed** (nux vomica): contains strychnine, exhibits neurostimulatory properties, requires particular attention to safety
- **Activated Charcoal**: used for adsorption/detoxification purposes

Homeopathic formulations lack modern pharmacological basis at the molecular mechanistic level. The TxGNN model's knowledge graph cannot effectively map the active components of such formulations to DrugBank IDs, preventing the prediction workflow from initiating.

---

## Clinical Trial Evidence

Currently no relevant clinical trials are registered (TxGNN produced no predicted indications, therefore evidence search cannot be executed).

---

## Literature Evidence

Currently no literature is available for citation (TxGNN produced no predicted indications, therefore literature search cannot be executed).

---

## US Market Information

This combination formulation has **no approved marketing record in the United States** (number of NDAs: 0).

---

## Safety Considerations

> ⚠️ **Special Attention**: This formulation contains **Strychnos nux-vomica seed**, which contains strychnine, a component with high neurotoxic potential. Excessive use may cause convulsions or even death. Even when used in extremely diluted homeopathic dosage forms, suspension of advancement is recommended pending completion of safety review.

Currently no other safety data available (warnings, contraindications, drug interactions all lack data). For complete safety information, please refer to the manufacturer's labeling.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This drug cannot proceed with the drug repurposing assessment workflow due to three fundamental obstacles:
1. TxGNN model produced no predicted indications for this combination (predicted_indications is empty)
2. No DrugBank ID exists, preventing mechanistic association analysis
3. Contains highly toxic ingredients (nux vomica/strychnine), safety not established

**To proceed, the following is needed:**

- **Fundamental issue correction**: confirm whether this candidate drug is a valid drug repurposing research target; homeopathic combinations typically are not suitable for the TxGNN knowledge graph prediction framework
- **Component dissection assessment**: if research objectives are clearly defined, recommend instead conducting predictions using **single active components** (e.g., strychnine, Solidago virgaurea extract) as independent candidate molecules
- **Safety review**: obtain toxicological data for nux vomica-containing formulations, confirm safety threshold at intended concentration
- **Market positioning clarification**: if this formulation is a homeopathic preparation, its regulatory pathway (e.g., DSHEA dietary supplement, homeopathic OTC) has fundamental differences from the drug repurposing pathway; development objectives must first be clarified
- **Data completion** (if proceeding):
  - Download and parse the package insert PDF from the FDA website warnings/contraindications (corresponding to DG001)
  - Query the DrugBank API to obtain mechanism of action (corresponding to DG002)

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

